awmsg logo



golimumab (Simponi®)


Reference No. 1324

Publication date:
30/09/2016


Appraisal information

golimumab (Simponi®) 50 mg solution for injection
golimumab (Simponi®) Unspecified


Company: Merck Sharp & Dohme Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 29/09/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, golimumab (Simponi®) cannot be endorsed for use within NHS Wales in combination with methotrexate for the treatment of polyarticular juvenile idiopathic arthritis in children with a body weight of at least 40 kg, who have responded inadequately to previous therapy with methotrexate.
Statement of Advice (SOA)
Download